Last reviewed · How we verify
FYB206
FYB206 is a biosimilar of aflibercept (Eylea) that inhibits vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to reduce abnormal blood vessel growth in the eye.
FYB206 is a biosimilar of aflibercept (Eylea) that inhibits vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to reduce abnormal blood vessel growth in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.
At a glance
| Generic name | FYB206 |
|---|---|
| Sponsor | Formycon AG |
| Drug class | VEGF/PlGF inhibitor biosimilar |
| Target | VEGF-A, VEGF-B, PlGF |
| Modality | Biologic |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
FYB206 functions as a VEGF/PlGF trap by binding and sequestering these angiogenic factors, preventing their interaction with endothelial growth factor receptors. This mechanism reduces pathological neovascularization and vascular permeability in retinal diseases. As a biosimilar, it is designed to have equivalent efficacy and safety to the reference product aflibercept.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Diabetic macular edema
- Retinal vein occlusion
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
Key clinical trials
- Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients (PHASE1)
- Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |